H.C. Wainwright lowered the firm’s price target on Cogent Biosciences (COGT) to $12 from $14 and keeps a Buy rating on the shares following the Q1 report. The firm factored in an equity raise in Q4 of this year.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences: Promising Pipeline and Market Opportunities Drive Buy Rating
- Cogent Biosciences price target lowered to $7 from $8 at Baird
- Cogent Biosciences Advances with Promising Clinical Trials
- Cogent Biosciences reports Q1 net loss $72M
- Cogent Biosciences appoints Ray Frost as SVP, Market Access